Articles
By Wayne Kuznar
Reactive management and attention to possible infection is usually sufficient to treat dermatologic toxicities associated with targeted cancer therapies, said Barbara Burtness, MD, professor of medical oncology at Fox Chase Cancer Center in Philadelphia, Pennsylvania. Read More ›
“The 340B pricing program will continue to be modified to improve oversight and compliance, but it is here to stay,” according to Ron Schleif, MBA, BSPharm, cofounder and president of Oncology Reimbursement Management, a consulting firm. Read More ›
The Oncology Nursing Society (ONS) 39th Annual Congress attracted almost 3000 attendees from the United States and other parts of the world. Interviews with a random sample of attendees revealed that a common theme about what drew them to the meeting was the desire to expand their horizons—to gain new knowledge, meet new people, or to breathe new life into their careers. Read More ›
Attendees at the 10th Annual Conference of the Hematology/Oncology Pharmacy Association (HOPA) said there’s no place like HOPA for reconnecting with friends and colleagues in the pharmacy world, and learning from face-to-face time with their peers. Read More ›
Both oral and intravenous chemotherapy agents, and other drugs used to treat patients with cancer, can be hazardous to medical personnel who prepare, dispense, and administer these drugs, as well as to patients and their families. The Oncology Pharmacist spoke about safe-handling procedures and guidelines with Anne Marie Oberle, PharmD, BCOP, Advance Practice Clinical Oncology Pharmacist at the Kimmel Cancer Center at Thomas Jefferson University Hospital in Philadelphia, Pennsylvania. Read More ›
The American Society of Hematology (ASH) and the San Antonio Breast Cancer Symposium (SABCS) held back-to-back meetings in December 2013. The ASH annual meeting hosted approximately 20,000 attendees in New Orleans, Louisiana, where more than 5300 abstracts were presented, orally or as posters. About 7500 participants from more than 90 countries attended the breast cancer symposium. Below are selected brief highlights from these meetings. Read More ›
This article discusses approaches that have been used to examine potentially adverse outcomes in healthcare professionals who work with or are exposed to chemotherapy drugs: (1) the use of biomarkers to evaluate genotoxic damage; (2) adverse reproductive outcomes; and (3) the association of cancer with exposure to chemotherapy drugs. Read More ›
Several new drugs for the treatment of chronic lymphocytic leukemia (CLL) are considered major advances: 2 have been approved and 2 are under review by the US Food and Drug Administration (FDA). Read More ›
The optimal dosing of pomalidomide in the treatment of multiple myeloma has not been established. Yale University investigators compared continuous and intermittent dosing regimens, and while the intermittent schedule was associated with more toxicity, they concluded that it is preferable. Read More ›
For the first-line treatment of HER2-positive metastatic breast cancer, the combination of eribulin mesylate and trastuzumab yields higher response rates, with manageable toxicity. Read More ›